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Abstract 
Isolated mitochondria have served as useful tools for identifying the site(s) of impairment associated with respiratory chain-linked 
oxidative phosphorylation at the molecular level. Over the last three decades, a number of diseases associated with mitochondrial 
dysfunction have been identified. The literature is large and diverse. This paper presents abrief survey of the current state of knowledge 
concerning biochemical studies of mitochondrial diseases associated with skeletal muscle, such as mitochondrial myopathies and, with 
brain injury such as that induced by ischemia/reperfusion. Various mitochondrial preparations and assay conditions are evaluated. The 
importance of fresh tissue for the isolation of tightly coupled mitochondria nd the selection of suitable assay conditions for 
characterization have been demonstrated. Appropriate methodologies for isolation and characterization of tightly coupled mitochondria 
from both skeletal muscle and brain are presented. 
Keywords: Mitochondrial myopathy; Skeletal muscle mitochondria; Forebrain mitochondria; Respiratory chain; Oxidative phosphorylation; Ischemia; 
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1. Introduction 
Brain and skeletal muscle are tissues with a high aero- 
bic metabolism. Although the brain represents only about 
2% of adult human body weight, it accounts for approx. 
20% of total oxygen consumption. Its rate of oxygen 
consumption is near constant irrespective of physical and 
mental demand. In contrast, skeletal muscle represents 
about 30% of the total body weight but utilizes only some 
40% of total oxygen in the resting state. However, its 
oxygen consumption is increased several fold during phys- 
ical activity, and under certain circumstances skeletal mus- 
cle may account for more than 90% of the total body 
oxygen consumption [1]. It is apparent hat mitochondrial 
respiration plays a very important role in the energy 
metabolism of both brain and skeletal muscle. 
Over the last three decades, a number of diseases 
associated with mitochondrial dysfunction have been iden- 
tified (cf. Ref. [2-11], and isolated mitochondria have 
served as useful tools for identifying the site(s) of impair- 
ment associated with the respiratory chain-linked oxidative 
phosphorylation system at the molecular level. In this 
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paper, some recent studies of oxidative metabolism of 
isolated skeletal muscle and brain mitochondria derived 
from tissues in normal and diseased states are presented, 
with special emphasis on the importance of preparation 
and assay conditions. 
2. Mitochondrial myopathy 
The first report on mitochondrial disease appeared in 
1959, in which Emster, Ikkos and Luft pioneered biochem- 
ical studies of isolated mitochondria from skeletal muscle 
of a patient with severe hypermetabolism of non-thyroid 
origin [12]. Clinical, biochemical and ultrastructural stud- 
ies clearly demonstrated the critical role of respiratory 
control in living cells [13,14]. Since then there have been 
many reports on altered mitochondrial structure and func- 
tion in patients with neuromuscular diseases. The literature 
is large and diverse, and many review articles have ap- 
peared (cf. Refs. [2-11]). It is now evident that the mito- 
chondrion not only serves as the energy generator of the 
cell, but also plays a crucial role in the genetic regulation 
of cellular energy metabolism, with important implications 
for various biological functions. 
In clinically related biochemical studies, the site(s) of 
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abnormality may be associated with deficiency of one or 
more respiratory chain enzyme(s). Impairments of respira- 
tory chain-linked electron transfer in complexes I, III and 
IV have been reported (cf. Refs. [9,15]). In many of these 
studies, however, the defects were identified in only a 
single patient and were not - -  or could not - -  be repeated 
because of the invasive nature of muscle biopsy. Further- 
more, conflicting conclusions from biopsy specimens of 
apparently the same clinical disease have been reported by 
various laboratories. A pertinent example is the mitochon- 
drial encephalomyopathy, Kearns Sayre syndrome. Diver- 
sity of biochemical studies may be explained by differ- 
ences in experimental techniques for isolation and assay of 
mitochondrial preparations, by the constraint of parameters 
measured because of a very small sample size and patient 
selection; several defects that result in a systemic impair- 
ment of mitochondrial function may be characterized by 
very similar clinical features. It is essential, therefore, to 
establish what the limitation of the type of preparation and 
assay procedures are, and what, if any, artifactual problems 
may arise from the isolation and characterization f mito- 
chondria. 
2.1. Preparation of intact mitochondria nd mitochondrial 
fragments 
Mitochondrial preparations have been isolated from both 
fresh [16-21] and frozen [18] skeletal muscle; however, 
tightly coupled intact mitochondria can only be isolated 
from fresh tissue. Mitochondria isolated from frozen tissue 
consist of broken mitochondria and membrane fragments. 
Crude mitochondrial preparations from both fresh and 
frozen tissues have been used for biochemical studies. In 
addition, many biochemical studies reported in the litera- 
ture have been done with crude mitochondrial prepara- 
tions, often referred to as 'post-nuclear supernatant' by 
some investigators [22,23]. 
There are crucial differences between skeletal muscle 
and other tissues, such as heart and liver, which necessitate 
special attention for the isolation of tightly coupled mito- 
chondria [16]. As compared to other organs, only a small 
portion of the total mass of skeletal muscle consists of 
mitochondria, the bulk of the tissue being myofibrils. 
Furthermore, skeletal muscle contains a relatively high 
content of Ca 2+, which may damage the mitochondria 
during the isolation process. An additional difficulty is that 
in skeletal muscle the separation of mitochondria from 
other cellular components is hard in a non-electrolyte 
medium (e.g., isotonic sucrose), in contrast o the case of 
heart or liver. The myofibrils tend to give rise to a 
gelatinous consistency in a non-electrolyte medium, mak- 
ing separation of the mitochondria difficult. The isotonic 
electrolyte medium developed by Chappel and Perry [24] 
has been found to be very successful for the isolation of 
intact skeletal muscle mitochondria. The introduction of 
proteinase in the homogenization medium has also proved 
useful by facilitating the separation of mitochondria from 
other cellular components [17]. Consequently, both the 
quality and the yield of mitochondrial preparations have 
been greatly improved. With consideration of these param- 
eters, a method for the isolation of intact, tightly coupled 
skeletal muscle mitochondria from small quantities of 
biopsy specimens has been developed [ 17,21 ]. This method 
has also been successfully applied to fresh autopsy speci- 
mens obtained as late as 3 h after death, with no detrimen- 
tal effects on mitochondrial functions [15]. Therefore, one 
can derive pertinent data on mitochondrial energy 
metabolism in relatively fresh autopsy tissues. 
2.2. Characterization of mitochondrial preparations 
With isolated, intact mitochondrial preparations, both 
the respiratory chain-linked oxidative phosphorylation a d 
partial reactions of the respiratory chain have been used to 
characterize the electron transfer and energy coupling ca- 
pacities. In crude mitochondrial preparations from either 
fresh or frozen muscle, only the rate(s) of electron transfer 
of partial reactions of the respiratory chain had been 
measured. The energy coupling capacity of crude prepara- 
tions could not be measured because of their undefined 
composition. Even in fresh biopsy specimens, studies of 
partial reactions cannot provide quantitative data on the 
individual enzymes (or enzyme complexes) measured in 
some cases. Since some mitochondria may remain intact, 
they are not permeable to substrates such as NADH and 
thus enzyme activities will be severely underestimated. 
Although quantitative information regarding individual en- 
zymes (or enzyme complexes) can be derived from studies 
of partial reactions (e.g., in sonicated suspensions), these 
results cannot reveal how well the enzyme complexes 
interact with each other. Measurements of the rates of 
partial reactions together with those of the succinate oxi- 
dase and the antimycin-sensitive NADH oxidase could 
resolve this problem. Unfortunately, there have been only 
a few cases in which NADH and/or succinate oxidase 
activities were also measured. The diversity and complex- 
ity of biochemical studies in this field, and the difficulties 
in comparing the results reported from different laborato- 
ries, are apparent and could be rationalized by appropriate 
and consistent methodologies for isolation and charac- 
terization. 
2.3. Systematic approaches to determining respiratory 
chain-linked electron transfer and energy coupling activi- 
ties 
In this section a systematic approach based on experi- 
mental data derived from studies on human skeletal muscle 
mitochondria is presented. These data clearly demonstrate 
the importance of preparation and assay conditions in 
identifying the site(s) of functional impairment. The tech- 
niques employed are straightforward and can be readily 
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Table 1 
Cytochrome contents of human skeletal muscle mitochondrial preparations from Keams Sayre syndrome patients and controls 
23 
Tissue Source Cytochrome content (nmol/mg prot.) ~ 
a a 3 b c + c I 
Fresh biopsies Patients (n = 4) 0.08 ± 0.01 0.14 ± 0.05 0.19 -+ 0.04 0.65 ± 0.08 
Fresh autopsy Patient-S 0.10 0.14 0.20 0.69 
Frozen autopsy Patient-S 0.14 0.15 0.24 0.32 
Fresh biopsies Controls 0.30 ± 0.05 0.36 ± 0.09 0.25 _ 0.02 0.50 ± 0.02 
Data were compiled from Lee et al. [15] and Martens et al. [25]. 
Values are the mean _+ S.E, for fresh biopsies from patients and controls. 
reproduced in most laboratories. Complete analyses (isola- 
tion and characterization f mitochondria) can be accom- 
plished with 1 gram wet weight of skeletal muscle. 
Site of impairment of electron transfer from cytochrome 
c to cytochrome oxidase. Kearns Sayre syndrome (KSS) is 
one of the most intensely studied mitochondrial diseases. 
Four kinds of conclusions regarding the impairment of 
mitochondrial electron transfer have been reported [25]. 
These include: (i) cytochrome oxidase deficiency [26-28]; 
(ii) generalized eficiency of respiratory chain complexes 
and/or coenzyme Q [29-31]; (iii) an unidentified lesion 
without cytochrome oxidase deficiency [32]; and (iv) im- 
paired electron transfer from cytochrome c to cytochrome 
oxidase with cytochrome oxidase deficiency and excess 
cytochrome c [25,33,34]. 
Our data indicate that skeletal muscle mitochondrial 
preparations from four fresh biopsy and one autopsy speci- 
mens of KSS patients were tightly coupled with both 
succinate and NAD-linked substrates. The accompanying 
phosphorylating efficiencies with both substrates were in 
the normal range; however, state 3 rates of respiration with 
either succinate or NAD-linked substrates were consider- 
ably slower than those of controls. Although the cy- 
tochrome oxidase activity was also slower than that of 
controls, it was considerably faster than the rate with either 
succinate or NAD-linked substrates [25]. This would indi- 
cate that the site of impairment causing the depressed 
respiratory rates seen with succinate and NAD-linked sub- 
strates cannot be due to cytochrome oxidase and/or a 
defect on the path of electron transfer from cytochrome 
oxidase to oxygen. Spectrophotometric analyses of the 
mitochondrial cytochromes showed nearly 70% deficiency 
in cytochrome oxidase and a 30% excess in c-cytochro- 
rues. Steady state kinetics analyses of the cytochromes 
revealed a cross-over point between cytochrome c and 
cytochrome oxidase. These data clearly demonstrated that 
the site of impairment in electron transfer of NADH and 
succinate oxidase occurred between cytochrome c and 
cytochrome oxidase [25]. The precise mechanism of the 
impairment is not known at the present time. Inhibition of 
electron transfer from cytochrome c to cytochrome oxi- 
dase will cause accumulation of reduced forms of the 
Table 2 
Respiratory and phosphorylating activities of isolated skeletal muscle mitochondria from a LHON patient and controls 
Substrates Respiratory rate (nmol O/min per mg prot.) ~ RCIX ADP/O 
state 3 state 3U b 
Pyruvate + malate 
Patient 158 
Control (n = 6) 154 _+ 8 
Glutamate + malate 
Patient 167 
Control (n = 3) 165 ÷ 13 
Succinate (+ rotenone) 
Patient 188 
Control (n = 6) 175 _+ 13 
Ascorbate + TMPD 
Patient 437 
Control (n = 4) 404 _+ 76 
150 3.1 3.1 
169 + 20 4.2 + 0.4 3. I ± 0.2 
158 5.1 3.0 
193+ 15 7.4+ 1.5 3.2+0.1 
142 2.2 1.9 
177_+ 14 3.2_+0.2 1.8_+0.1 
The respiratory rates were measured polarographically [21]. The reaction mixture consisted of 150 mM sucrose, 25 mM Tris-Cl, 10 mM phosphate (pH 
7.5) and 0.5-0.8 mg mitochondrial protein. Total volume = 1.0 ml; temperature= 30°C. Substrates: 5 mM glutamate; 2.5 mM malate; 5 mM 
succinate + 1 /.LM rotenone; 10 mM ascorbate + 0.5 mM TMPD (tetramethyl phenylenediamine). State 3 and state 3U respiratory rates were initiated upon 
addition of 270 /xM ADP and 0.5 tzM FCCP, respectively. 
a Values for controls are the mean + S.E. 
b Abbreviations: tate 3U = uncoupled rate; RCI = respiratory control index. 
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respiratory chain carriers on the substrate side of cy- 
tochrome c and, consequently, promote and/or accelerate 
the formation of hydroperoxide, causing injury to mito- 
chondrial structure and function. 
It is well established that cytochrome c is a peripheral 
protein, whereas cytochrome c1 is an integral protein of 
the mitochondrial inner membrane. The contents of cy- 
tochromes a, a 3, b and c + c~ of mitochondrial prepara- 
tions, isolated from fresh and frozen skeletal muscle au- 
topsy specimens of a patient, have been determined. As 
shown in Table 1, the contents of cytochromes a, a 3 and b 
were comparable between mitochondrial preparations from 
fresh and frozen tissues, whereas the content of c-cyto- 
chromes in the mitochondrial preparation from frozen tis- 
sue was less than half of the c-cytochromes seen in the 
mitochondrial preparations from fresh autopsy tissue. These 
data indicate that more than half of the c-cytochromes seen 
in mitochondrial preparations from fresh specimens disso- 
ciated from the membrane during the freezing and thawing 
and/or isolation process, strongly supporting the conclu- 
sion that the excess c-cytochromes seen in mitochondrial 
preparations from fresh tissue is cytochrome c rather than 
cytochrome c~. Dissociation of cytochrome c from the 
mitochondrial membrane was also seen in mitochondrial 
preparations from frozen skeletal muscle of normal rats. 
These findings raise a very important point. Freezing and 
thawing of tissue appear to alter the binding of 
membrane-bound enzyme(s). If frozen tissue specimens 
were initially used, the excess cytochrome c associated 
with the mitochondrial membranes of KSS patients would 
have been missed. This further emphasizes the necessity to 
use fresh tissue for biochemical studies. 
Defect in complex I and its binding to the mitochondrial 
inner membrane. A patient with an undefined encephalopa- 
thy who presented some clinical characteristics of Leber's 
Hereditary Optic Neuropathy (LHON) has been investi- 
gated [35]. Biochemical studies were carried out on a 
mitochondrial preparation isolated from a fresh skeletal 
muscle biopsy. As shown in Table 2, mitochondria were 
tightly coupled and exhibited normal respiratory rates and 
phosphorylating efficiencies with pyruvate + malate, gluta- 
mate + malate and succinate (+rotenone) as substrates. 
The cytochrome contents were within the normal ranges. 
However, the NADH oxidase was found to be very labile. 
As shown in Table 3, nearly 95% of its activity was lost 
when intact mitochondria were subjected to mild mechani- 
cal agitation (10 s sonication). Addition of external cy- 
tochrome c did not increase the activity. Under the same 
condition, more than 90% of the activity was retained in 
controls. A severe impairment in NADH-cytochrome-c 
oxidoreductase activity was also seen. On the other hand, 
the succinate cytochrome-c oxidoreductase was virtually 
unaffected. These data indicate that the site of impairment 
was associated with Complex I (NADH-UQ oxidoreduc- 
tase). The fact that complex I can function properly under 
normal conditions, but is highly susceptible to physical 
Table 3 
NADH oxidase and NADH- or succinate-cytochrome-c oxidoreductase 
activities in suspensions of disrupted human skeletal muscle mitochondria 
from a LHOH patient and control 
System Rate (n eq. 2e - /  
min per mg prot,) ~ 
Patient Control 
NADH oxidase 
(A) + NADH 2.5 196 
(B) as (A) +Cyt. c 2.8 247 
(C) as (B) + rotenone 2.1 42 
(D) as (C) + antimycin A 2.1 24 
NADH- or succinate-c~,tochrome-c oxidoreductase 
(A) +NADH+Cyt .  c +KCN 4.7 167 
(B) as (A) +rotenone 3.8 33 
(C) as (B) + succinate 22.6 55 
(D) as (C) + antimycin A 3.2 29 
The activities of NADH oxidase and NADH or succinate cytochrome-c 
oxidoreductase were determined spectrophotometrically s described in 
[21]. The assay mixture consisted of 150 mM sucrose, 25 mM Tris-CI, 10 
mM phosphate (pH 7.5) and 0.1-0.2 mg protein of sonic mitochondrial 
suspensions. Others when indicated: 200 /xM NADH, 5 mM succinate, 
10-40/xM and 200/xM cytochrome c for NADH oxidase and NADH or 
succinate cytochrome-c oxidoreductase, respectively, 1.3 mM KCN, 1 
/xM rotenone and 3 /xg antimycin. 
changes uch as mechanical stress, suggests that the bind- 
ing and/or assembling of complex I subunits to the mito- 
chondrial inner membrane is abnormal in this disorder. 
These findings would not have been possible, if our studies 
would have been carried out with frozen tissue. 
3. Brain ischemia and reperfusion 
It is well documented in the literature that mitochon- 
drial respiratory activities of brain are impaired by tran- 
sient ischemic events, and under certain conditions that 
restore respiratory activities to normal evels upon reperfu- 
sion [36-39]. The cause of ischemia-induced injury of 
mitochondria had been postulated but had not as yet been 
established. Growing evidence supports roles for both 
disruption of cellular Ca 2÷ homeostasis [40] and for perox- 
idative processes [41-45] in ischemia/reperfusion nduced 
injury. However, the role of mitochondrial Ca 2÷ transport 
in the development of ischemic brain injury has been 
controversial [40,46,47]. Undoubtedly, in many cases (if 
not all), variations in preparations and assay conditions 
employed by different investigators have played an impor- 
tant role in establishing these discrepancies. 
3.1. Forebrain mitochondrial preparation 
In contrast o the case of heart or liver, the isolation of 
mitochondria from brain has been complicated by its high 
myelin and lipid contents. Separation of mitochondria from 
other membranous constituents has been facilitated by 
increasing the density of the fractionation medium with 
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Ficoll. However, because of the multiple steps involved in 
purification and the relatively poor recovery of mito- 
chondria, 4 to 6 rats have been required to derive sufficient 
amounts of mitochondria for biochemical assays [48,49]. 
These requirement have made studies of mitochondrial 
functions in brain injury difficult. Although a span of a 
few minutes between handling of two rats may not have 
significant effects in the case of liver or heart, it may lie at 
the boundary of life and death in the case of brain, 
especially with brain derived from head-injured rats. A 
simple and fast method for isolation and purification of 
forebrain mitochondria has recently been developed [50,51]. 
This procedure is particularly valuable for preparations 
from brain following ischemia and trauma, since mito- 
chondria derived from the brain of one injured rat is 
sufficient to run a number of assays, which will allow 
study of the effect of ischemic duration, and of the kinetics 
of brain injury on mitochondrial functions. This would not 
be possible if several rat brains were required for mito- 
chondrial preparations. 
3.2. lschemic injuo' to.figrebrain mitochondria and cellular 
calcium homeostasis 
Using a reversible, 7-vessel occlusion rat model of 
ischemia, and the isolation and purification method of 
forebrain mitochondria recently developed in our labora- 
tory, the effects of the cessation of forebrain blood flow on 
the respiratory chain-linked electron transfer and energy 
transduction were systematically evaluated [50]. As shown 
in Table 4, the state 3 respiratory rate of ischemic brain 
mitochondria (I-RBM/15") was severely decreased. Little 
or no respiratory control was seen. When the assay medium 
was supplemented with 0.4 mM EDTA, the respiratory 
activity exhibited by ischemic mitochondria was compara- 
ble to that of control. Prolonged ischemia of 30 min 
resulted in severe impairment of state 3 respiratory rate 
and little effect on state 4 activity, which could only be 
partially prevented by EDTA. Virtually identical results 
were obtained when EDTA was replaced by EGTA or 
ruthenium red, an inhibitor of mitochondrial Ca 2+ uptake. 
Essentially identical results were obtained with pyruvate 
and malate as well as with succinate (+rotenone) as 
substrates. If EDTA was initially included in the assay 
medium, as suggested in the literature [36,38,39,52,53], the 
protection by EDTA or EGTA against ischemic injury 
would not have been observed. EDTA or EGTA had no 
significant effect on respiratory activities of control mito- 
chondria with either succinate or NAD-linked substrates. A 
decreased energy-linked Ca 2 + uptake was also found with 
the ischemic mitochondria. These data strongly suggest 
that ischemic insult disturbs cellular Ca 2+ homeostasis, 
causing an increase in cytosolic Ca 2+ concentration which 
results in excessive association of Ca ~-~ with the mito- 
chondrial membrane and an inhibition of the respiratory 
chain-linked oxidative phosphorylation [50]. 
3.3. Ischemia / reperfusion-induced injuo' of forebrain 
mitochondria nd protection by ascorbate 
Further damage to the respiratory chain-linked energy 
transducing processes of rat forebrain mitochondria oc- 
curred during reperfusion [54]. As shown in Table 4, a 5 h 
period of reperfusion following 30 min of ischemia re- 
sulted in a further decrease in both state 3 and state 4 
respiratory rates (61 and 57%, respectively) from ischemic 
values with glutamate + malate as substrates. Furthermore, 
the presence of 0.4 mM EGTA did not restore the respira- 
tory activities of 5 h reperfused rat forebrain mitochondria 
to the level observed with 30 min ischemic mitochondria. 
Table 4 
Effects of EDTA or EGTA and of ascorbate treatment on ischemia nd ischemia/reperfusion induced injury to the respiratory activities of rat forebrain 
mitochondrial preparations with glutamate + malate as substrates a 
Preparation Others Respiratory rates (n atoms O/min per mg prot.) b 
Controls (n = 18) 
I-RBM [1 = 15"] (n = 9) 
I-RBM [1 = 15"] (n = 9) +EDTA 
I-RBM [1 = 30"] (n = 6) 
I-RBM [l = 30"] (n = 6) +EDTA 
I/R-RBM (n = 5) ( I /R  = 30'/5 h) 
I/R-RBM (n = 5) ( I /R  = 30'/5 h) +EGTA 
I/R-RBM (n = 5) ( I /R  = 30'/5 h) +Asc [5'pre-I] 
I/R-RBM (n = 3) ( I /R  = 30'/5 h) +Asc [10'pre-R] 
I/R-RBM (n = 3) ( I /R  = 30'/5 h) +Asc [60'post-R] 
I-RBM [1 = 30'] (n = 3) +Asc [5'pre-I] 
Data were compiled from Sciamanna nd Lee [54]. 
b Values are the mean _ S.E. 
state 3 state 4 
153.3 _+ 13.2 33.6 +_ 7.6 
54.4-t- 10.0 44.4+ 15.1 
162.1 ±25.4 34.3 + 15.1 
50.1 + 14.9 45.6+ 18.7 
89.8 _+ 18.8 33.8 + 13.6 
19.7 + 6.7 19.7 _+ 6.7 
33.7 _+ 9.0 30.2 + 6.6 
128.4 + 14.5 37.5 + 8.5 
90.8 + 28.4 40.2 + 8.5 
97.3 _ 24.9 36.3 + 7.6 
56.6 + 1.8 32.1 + 8.9 
Abbreviations: I-RBM = ischemic rat brain mitochondria; I/R-RBM = ischemic/reperfused rat brain mitochondria; I /R  = 30'/5 h, 30 min ischemic/5 
h reperfusion: 5'pre-I, 0.8 mg ascorbate/kg body weight was administered 5 rain prior to the onset of ischemia; 10' pre-R, 0.8 mg ascorbate/kg body 
weight was administered 10' pre-reperfusion; 60'post-R, 0.8 mg ascorbate/kg body weight was administered 60 min post-reperfusion. 
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Similar results were also seen when glutamate + malate 
were replaced by pyruvate + malate or succinate 
( + rotenone). 
Forebrain mitochondrial respiration was protected by 
administering 0.8 mg ascorbate/kg body weight in vivo 
prior to the onset of ischemia. In order to assess whether 
this protection was dose dependent, rats were treated with 
varying amounts of ascorbate via intraperitoneal injection 
5 min prior to the onset of ischemia. Fig. 1A and 1B show 
the effect of varying doses of ascorbate, administered in
vivo, on rat forebrain mitochondrial respiration following 
30 min of ischemia nd 5 h of reperfusion. Fig. 1A shows 
a dose-dependent protection by ascorbate against is- 
chemia/reperfusion-induced injury to forebrain mitochon- 
drial oxidative metabolism. Optimal protection was ob- 
served with 0.8 mg ascorbate/kg body weight. The respi- 
ratory rates increased more than 6-fold and less than 2-fold 
from untreated values, for State 3 and State 4, respectively, 
to values near controls (cf. Table 4). Ascorbate treatment 
exhibited no protective ffect against injury induced by 
ischemia lone (Table 4). Similar protection occurred, but 
to a lesser extent, with succinate (+rotenone) as the 
respiratory substrate (State 3: less than 3-fold increase 
from untreated, or 60% of the control values). An addi- 
tional protection was provided by the presence of 0.4 mM 
EGTA in the assay medium (Fig. 1B). These data indicate 
that the respiration with NAD-linked substrates i  more 
susceptible to peroxidative damage than that with succi- 
nate. Treatment with 1.6 mg or more ascorbate/kg body 
weight resulted in a significant decrease in protection from 
ischemia/reperfusion-induced injury (Fig. 1). Treatment 
with 3.5 mg ascorbate/kg body weight abolished ascor- 
bate-mediated protection. Reperfusion-induced injury to 
Ca 2+ transport was also protected by an optimal amount of 
ascorbate (i.e., 0.8 mg/kg body weight) [54]. The ascor- 
bate protection was dose-dependent, which reflects its 
prooxidant property at higher concentrations as docu- 
mented in the literature [55,56]. 
Treatment of animals with the optimal amount (0.8 
mg/kg body weight) of ascorbate 10 min prior to the 
onset of reperfusion, only partial protection was observed. 
State 3 rates were 59% of control values. Similar protec- 
tion was observed with ascorbate treatment at 60 min 
post-reperfusion as was seen with treatment at 10 min 
pre-reperfusion. I  both cases, the State 4 rates were near 
control values. These results demonstrate he importance 
of early intervention i the ischemia/reperfusion event. A 
protective role for ascorbate against ischemia/reperfusion 
injury during cardiac by-pass surgery has also been 
demonstrated [57,58]. Reactive oxygen species can initiate 
lipid peroxidation which may cause inhibition of mito- 
chondrial respiration. Protection of mitochondrial energy 
transducing processes by ascorbate strongly suggests a 
major role for oxygen radical-mediated processes in is- 
chemia/reperfusion-induced injury. 
One would predict that a defect in the pathway of 
O 
o 
v 
o 
160 
120 
80 
40 
0 
• State 3 
~/m A State 4 
k• ..... 
I , I , I 
! 2 3 
mg Aseorbate 
/kg body weight 
160 
°r-t 
E~ 120 
o 
o 80 
• ~ 40, 
o 
0 
0 
N~ State  3 
• State  4 
~•.....• ............... • ..................................... ] 
I , I ~ I 
1 2 3 
nag Aseorbate 
/ kg  body  we ight  
Fig. 1. Dose dependence of protection by ascorbate against ischemia/re- 
perfusion-induced injury to forebrain mitochondrial respiration. The dura- 
tion of ischemia nd reperfusion are 30 min and 5 h, respectively. The 
assay medium consisted of 150 mM sucrose, 25 mM Tris-HCl, and 10 
mM phosphate buffer (pH 7.4) in the absence of (A) and in the presence 
of (B) 0.4 mM EGTA. 5 mM glutamate+ 2.5 mM malate were the 
substrates and state 3 respiration was initiated upon addition of 270 /zM 
ADP. Total volume = 1.0 ml; temperature = 30 ° C. From [54] with per- 
mission. 
electron transfer along the respiratory chain would have 
both extensive and complex effects on mitochondrial nd 
cellular metabolism. The most obvious effect would, of 
course, be an impaired rate of ATP production resulting 
from a decreased rate of mitochondrial substrate utiliza- 
tion. Additionally, a block in electron transfer along the 
respiratory chain could also cause serious secondary dam- 
age to the mitochondrial membrane and the cell as a whole 
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as a result of the buildup of toxic peroxides and other 
reactive species of oxygen [59-61]. 
In conclusion, the availability of appropriate method- 
ologies for isolation and characterization f tightly coupled 
mitochondria provide us with useful tools for examining 
the functional activities of respiratory chain-linked energy 
transduction. Analyses of these parameters in conjunction 
with clinical assessment will provide means for identifying 
the underlying biochemical lesion at the molecular level in 
these disorders and facilitate the design of therapeutic 
intervention, in addition to other studies of mitochondrial 
disorders, such as those on noninvasive spectroscopic 
methods and on mitochondrial DNA analyses that are 
reviewed in several papers presented at this symposium. 
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